Pitavastatin sensitizes the EGFR-TKI associated resistance in lung cancer by inhibiting YAP/AKT/BAD-BCL-2 pathway

Abstract Background Despite effective strategies, resistance in EGFR mutated lung cancer remains a challenge. Metabolic reprogramming is one of the main mechanisms of tumor drug resistance. A class of drugs known as “statins” inhibit lipid cholesterol metabolism and are widely used in patients with...

Full description

Bibliographic Details

Published in:	Cancer Cell International
Main Authors:	Jie Liu, Jialei Fu, Ping Fu, Menghan Liu, Zining Liu, Bao Song
Format:	Article
Language:	English
Published:	BMC 2024-06-01
Subjects:	Pitavastatin EGFR-TKI Drug resistance Lung cancer YAP
Online Access:	https://doi.org/10.1186/s12935-024-03416-z